95 publications in the database
| # | PMID | Citation | Number of variants |
|---|---|---|---|
| 1 | 24325356 | Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013.369(25):2379-2390. doi:10.1056/NEJMoa1311347 | 48 |
| 2 | 29424450 | Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A. Mayo CALR mutation type classification guide using alpha helix propensity. Am J Hematol. 2018.93(5):E128-E129. doi:10.1002/ajh.25065 | 39 |
| 3 | 24366362 | Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014.123(10):1544-1551. doi:10.1182/blood-2013-11-539098 | 24 |
| 4 | 24791854 | Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014.28(12):2300-2303. doi:10.1038/leu.2014.148 | 18 |
| 5 | 31554376 | Vu HA, Thao TT, Dong CV, et al. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia. Asian Pac J Cancer Prev. 2019.20(9):2775-2780. Published 2019 Sep 1. doi:10.31557/APJCP.2019.20.9.2775 | 17 |
| 6 | 27504244 | Kondo T, Tasaka T, Tomioka N, et al. Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms. Springerplus. 2016.5(1):1146. Published 2016 Jul 22. doi:10.1186/s40064-016-2829-6 | 15 |
| 7 | 24325359 | Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013.369(25):2391-2405. doi:10.1056/NEJMoa1312542 | 14 |
| 8 | 29306106 | Gángó A, Mózes R, Boha Z, et al. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms. Leuk Res. 2018.65:42-48. doi:10.1016/j.leukres.2017.12.005 | 14 |
| 9 | 25746303 | Li N, Yao QM, Gale RP, et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations. Leuk Res. 2015.39(5):510-514. doi:10.1016/j.leukres.2015.02.006 | 13 |
| 10 | 26343915 | Riera L, Osella-Abate S, Benevolo G, et al. Novel CALR somatic mutations in essential thrombocythaemia. Br J Haematol. 2016.173(5):797-801. doi:10.1111/bjh.13638 | 13 |
| 11 | 25023898 | Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014.7:48. Published 2014 Jul 15. doi:10.1186/s13045-014-0048-6 | 11 |
| 12 | 25398833 | Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015.100(2):e46-e48. doi:10.3324/haematol.2014.115113 | 11 |
| 13 | 26375990 | Guo H, Chen X, Tian R, et al. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms [published correction appears in PLoS One. 2015.10(10):e0141173]. PLoS One. 2015.10(9):e0138250. Published 2015 Sep 16. doi:10.1371/journal.pone.0138250 | 11 |
| 14 | 25801912 | Palandri F, Latagliata R, Polverelli N, et al. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015.29(6):1344-1349. doi:10.1038/leu.2015.87 | 10 |
| 15 | 27521277 | Panovska-Stavridis I, Eftimov A, Ivanovski M, et al. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk. 2016.16(8):477-481. doi:10.1016/j.clml.2016.04.019 | 10 |
| 16 | 24732593 | Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014.28(9):1912-1914. doi:10.1038/leu.2014.138 | 9 |
| 17 | 32395211 | Liu YC, Lee CP, Yeh TJ, et al. Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocythemic Patients. Mediterr J Hematol Infect Dis. 2020.12(1):e2020022. Published 2020 May 1. doi:10.4084/MJHID.2020.022 | 9 |
| 18 | 31882869 | Belcic Mikic T, Pajic T, Sever M. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms. Sci Rep. 2019.9(1):19838. Published 2019 Dec 27. doi:10.1038/s41598-019-56236-x | 8 |
| 19 | 25015052 | Chen CC, Gau JP, Chou HJ, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014.93(12):2029-2036. doi:10.1007/s00277-014-2151-8 | 7 |
| 20 | 25934766 | Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015.100(7):893-897. doi:10.3324/haematol.2014.118299 | 7 |
| 21 | 25301336 | Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014.124(15):2465-2466. doi:10.1182/blood-2014-07-588426 | 5 |
| 22 | 25729726 | Park SH, Kim SY, Lee SM, et al. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea. Ann Lab Med. 2015.35(2):233-237. doi:10.3343/alm.2015.35.2.233 | 5 |
| 23 | 24504025 | Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014.28(7):1552-1555. doi:10.1038/leu.2014.66 | 4 |
| 24 | 24569778 | Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014.28(7):1568-1570. doi:10.1038/leu.2014.83 | 4 |
| 25 | 25323779 | Wojtaszewska M, Iwoła M, Lewandowski K. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms. Acta Haematol. 2015.133(2):193-198. doi:10.1159/000366263 | 4 |
| 26 | 26071474 | Lin Y, Liu E, Sun Q, et al. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. Am J Clin Pathol. 2015.144(1):165-171. doi:10.1309/AJCPALP51XDIXDDV | 4 |
| 27 | 26227853 | Nunes DP, Lima LT, Chauffaille Mde L, et al. CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients. Blood Cells Mol Dis. 2015.55(3):236-240. doi:10.1016/j.bcmd.2015.07.005 | 4 |
| 28 | 27855276 | Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. J Mol Diagn. 2017.19(1):92-98. doi:10.1016/j.jmoldx.2016.08.006 | 4 |
| 29 | 31856623 | Polokhov DM, Ershov NM, Ignatova AA, et al. Platelet function and blood coagulation system status in childhood essential thrombocythemia. Platelets. 2020.31(8):1001-1011. doi:10.1080/09537104.2019.1704710 | 4 |
| 30 | 35016075 | Fabris S, Cattaneo D, Salerio S, et al. Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. Thromb Res. 2022.210:67-69. doi:10.1016/j.thromres.2021.12.021 | 4 |
| 31 | 24553179 | Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014.123(15):2416-2419. doi:10.1182/blood-2014-01-550434 | 3 |
| 32 | 26994960 | Monte-Mor Bda C, Ayres-Silva Jde P, Correia WD, et al. Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. Blood Cells Mol Dis. 2016.60:74-77. doi:10.1016/j.bcmd.2016.03.003 | 3 |
| 33 | 31250082 | Bonifacio M, Montemezzi R, Parisi A, et al. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. Ann Hematol. 2019.98(10):2339-2346. doi:10.1007/s00277-019-03741-8 | 3 |
| 34 | 31626697 | Lee JS, Kim HY, Kim M, Lee YK. A Novel Pathogenic CALR Exon 9 Mutation in a Patient with Essential Thrombocythemia. Lab Med. 2020.51(3):306-309. doi:10.1093/labmed/lmz064 | 3 |
| 35 | 24365789 | Chi J, Nicolaou KA, Nicolaidou V, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia. 2014.28(5):1152-1154. doi:10.1038/leu.2013.382 | 2 |
| 36 | 24402162 | Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014.28(7):1472-1477. doi:10.1038/leu.2014.3 | 2 |
| 37 | 24895336 | Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 2014.99(7):1184-1190. doi:10.3324/haematol.2014.107482 | 2 |
| 38 | 24986690 | Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014.124(7):1062-1069. doi:10.1182/blood-2014-05-578435 | 2 |
| 39 | 24997152 | Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica. 2014.99(11):1697-1700. doi:10.3324/haematol.2014.109249 | 2 |
| 40 | 25005031 | Shen H, Chao H, Ding Z, et al. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia. Leuk Lymphoma. 2015.56(3):820-822. doi:10.3109/10428194.2014.939963 | 2 |
| 41 | 25015940 | Qiao C, Sun C, Ouyang Y, et al. Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica. 2014.99(10):e182-e184. doi:10.3324/haematol.2014.109199 | 2 |
| 42 | 25037629 | Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014.124(16):2507-2615. doi:10.1182/blood-2014-05-579136 | 2 |
| 43 | 25103987 | Trifa AP, Popp RA, Cucuianu A, et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015.168(1):151-153. doi:10.1111/bjh.13076 | 2 |
| 44 | 25139350 | Allen C, Lambert JR, Linch DC, Gale RE. X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations. Blood. 2014.124(13):2091-2093. doi:10.1182/blood-2014-06-580183 | 2 |
| 45 | 25212275 | Cabagnols X, Defour JP, Ugo V, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia. 2015.29(1):249-252. doi:10.1038/leu.2014.270 | 2 |
| 46 | 25637689 | Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, et al. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2015.8(1):16-21. doi:10.1016/j.hemonc.2014.12.002 | 2 |
| 47 | 25661444 | Mondet J, Park JH, Menard A, et al. Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia. Haematologica. 2015.100(5):e176-e178. doi:10.3324/haematol.2014.118927 | 2 |
| 48 | 25873496 | Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Am J Clin Pathol. 2015.143(5):635-644. doi:10.1309/AJCPUAAC16LIWZMM | 2 |
| 49 | 26041426 | Machado-Neto JA, de Melo Campos P, de Albuquerque DM, et al. Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. Rev Bras Hematol Hemoter. 2015.37(3):211-214. doi:10.1016/j.bjhh.2015.03.012 | 2 |
| 50 | 26124496 | Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015.126(6):790-797. doi:10.1182/blood-2015-03-633404 | 2 |
| 51 | 26377485 | Wang J, Hao J, He N, Ji C, Ma D. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia. Miyeloproliferatif Neoplazisi ve Akut Lösemisi Olan Hastalarda Kalretikülin Mutasyon Profili. Turk J Haematol. 2016.33(3):180-186. doi:10.4274/tjh.2015.0220 | 2 |
| 52 | 26728869 | Shen W, Szankasi P, Sederberg M, et al. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. Br J Haematol. 2016.173(1):49-58. doi:10.1111/bjh.13921 | 2 |
| 53 | 27258562 | Sakr H, Clark Schneider K, Murugesan G, Bodo J, Hsi ED, Cook JR. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms. Appl Immunohistochem Mol Morphol. 2018.26(2):147-152. doi:10.1097/PAI.0000000000000391 | 2 |
| 54 | 27352261 | Haslam K, Conneally E, Flynn CM, et al. CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematol Oncol Stem Cell Ther. 2016.9(3):112-115. doi:10.1016/j.hemonc.2016.05.002 | 2 |
| 55 | 27444979 | Kim Y, Park J, Jo I, et al. Genetic-pathologic characterization of myeloproliferative neoplasms. Exp Mol Med. 2016.48(7):e247. Published 2016 Jul 22. doi:10.1038/emm.2016.55 | 2 |
| 56 | 27449473 | Magor GW, Tallack MR, Klose NM, et al. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. J Mol Diagn. 2016.18(5):707-718. doi:10.1016/j.jmoldx.2016.05.006 | 2 |
| 57 | 27535857 | Xu ZF, Li B, Liu JQ, et al. Zhonghua Xue Ye Xue Za Zhi. 2016.37(7):576-580. doi:10.3760/cma.j.issn.0253-2727.2016.07.007 | 2 |
| 58 | 29148089 | Venton G, Courtier F, Charbonnier A, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018.93(3):330-338. doi:10.1002/ajh.24973 | 2 |
| 59 | 29521158 | Rattarittamrong E, Tantiworawit A, Kumpunya N, et al. Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations. Hematology. 2018.23(9):613-619. doi:10.1080/10245332.2018.1448699 | 2 |
| 60 | 31776465 | Bartels S, Faisal M, Büsche G, et al. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis. Leukemia. 2020.34(5):1364-1372. doi:10.1038/s41375-019-0668-5 | 2 |
| 61 | 32971364 | Javorniczky NR, Wehrle J, Ihorst G, et al. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leuk Res. 2020.98:106454. doi:10.1016/j.leukres.2020.106454 | 2 |
| 62 | 34214802 | Lemoine S, Renard M, Bouvier A, et al. No detection of atypical one-base deletion of CALR exon 9 with fragment analysis: A molecular trap to avoid. Blood Cells Mol Dis. 2021.90:102589. doi:10.1016/j.bcmd.2021.102589 | 2 |
| 63 | 24441291 | Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014.28(6):1357-1360. doi:10.1038/leu.2014.33 | 1 |
| 64 | 24531734 | Hou HA, Kuo YY, Chou WC, Chen PH, Tien HF. Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome. Leukemia. 2014.28(7):1555-1557. doi:10.1038/leu.2014.71 | 1 |
| 65 | 24837467 | Lippert E, Mansier O, Migeon M, et al. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis. Haematologica. 2014.99(7):e98-e101. doi:10.3324/haematol.2014.107656 | 1 |
| 66 | 24850292 | Heuser M, Panagiota V, Koenecke C, et al. Low frequency of calreticulin mutations in MDS patients. Leukemia. 2014.28(9):1933-1934. doi:10.1038/leu.2014.165 | 1 |
| 67 | 24935260 | McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive. findings from retrospective analysis of a small patient cohort. Br J Haematol. 2014.167(2):276-278. doi:10.1111/bjh.12969 | 1 |
| 68 | 25103330 | Langabeer SE, Haslam K, Linders J, et al. Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Fam Cancer. 2014.13(4):659-663. doi:10.1007/s10689-014-9743-2 | 1 |
| 69 | 25173966 | Turon F, Cervantes F, Colomer D, Baiges A, Hernández-Gea V, Garcia-Pagán JC. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol. 2015.62(1):72-74. doi:10.1016/j.jhep.2014.08.032 | 1 |
| 70 | 25176567 | An W, Wan Y, Guo Y, et al. CALR mutation screening in pediatric primary myelofibrosis. Pediatr Blood Cancer. 2014.61(12):2256-2262. doi:10.1002/pbc.25211 | 1 |
| 71 | 25190754 | Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood. 2014.124(10):1691-1692. doi:10.1182/blood-2014-04-568410 | 1 |
| 72 | 25305205 | Broséus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014.124(26):3964-3966. doi:10.1182/blood-2014-06-583161 | 1 |
| 73 | 25316523 | Cui Y, Li B, Gale RP, et al. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol. 2014.7:77. Published 2014 Oct 15. doi:10.1186/s13045-014-0077-1 | 1 |
| 74 | 25366168 | Xu N, Ding L, Yin C, et al. A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Ann Hematol. 2015.94(5):865-867. doi:10.1007/s00277-014-2248-0 | 1 |
| 75 | 25543699 | Cui Y, Li B, Jiang Q, et al. Zhonghua Xue Ye Xue Za Zhi. 2014.35(12):1069-1073. doi:10.3760/cma.j.issn.0253-2727.2014.12.005 | 1 |
| 76 | 25573593 | Pósfai É, Marton I, Király PA, et al. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis. Pathol Oncol Res. 2015.21(3):751-758. doi:10.1007/s12253-014-9885-4 | 1 |
| 77 | 25682604 | Plompen EP, Valk PJ, Chu I, et al. Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica. 2015.100(6):e226-e228. doi:10.3324/haematol.2014.120857 | 1 |
| 78 | 25838280 | Bonzheim I, Mankel B, Klapthor P, et al. CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation. Blood. 2015.125(14):2309-2311. doi:10.1182/blood-2014-12-616847 | 1 |
| 79 | 25858548 | Sano H, Ohki K, Park MJ, et al. CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8. 21). Br J Haematol. 2015.170(3):391-397. doi:10.1111/bjh.13439 | 1 |
| 80 | 25959795 | Sazawal S, Singh N, Mahapatra M, Saxena R. Calreticulin mutation profile in Indian patients with primary myelofibrosis. Hematology. 2015.20(10):567-570. doi:10.1179/1607845415Y.0000000018 | 1 |
| 81 | 25999449 | Loghavi S, Pemmaraju N, Kanagal-Shamanna R, et al. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015.125(21):3360-3363. doi:10.1182/blood-2015-03-632893 | 1 |
| 82 | 26064712 | Nazha B, Garcia G, Kandov R, Odaimi M. Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome. Case Rep Hematol. 2015.2015:161764. doi:10.1155/2015/161764 | 1 |
| 83 | 26904322 | Langabeer SE, Haslam K, O'Brien D, et al. Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia. Case Rep Hematol. 2016.2016:6545861. doi:10.1155/2016/6545861 | 1 |
| 84 | 27009537 | Panovska-Stavridis I, Eftimov A, Ivanovski M, et al. Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation. Clin Lymphoma Myeloma Leuk. 2016.16(5):e55-e57. doi:10.1016/j.clml.2016.02.039 | 1 |
| 85 | 27013444 | Theocharides AP, Lundberg P, Lakkaraju AK, et al. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood. 2016.127(25):3253-3259. doi:10.1182/blood-2016-02-696310 | 1 |
| 86 | 27699446 | Diamond JM, de Almeida AM, Belo HJ, da Costa MP, Cabeçadas JM, Abecasis MM. CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene. Ann Hematol. 2016.95(12):2101-2104. doi:10.1007/s00277-016-2827-3 | 1 |
| 87 | 27758825 | Chauveau A, Nibourel O, Tondeur S, et al. Absence of CALR mutations in JAK2-negative polycythemia. Haematologica. 2017.102(1):e15-e16. doi:10.3324/haematol.2016.154799 | 1 |
| 88 | 27917774 | De Kock A, Booysen C. Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm. S Afr Med J. 2016.106(12):1260-1262. Published 2016 Dec 1. doi:10.7196/SAMJ.2016.v106.i12.10769 | 1 |
| 89 | 28747287 | Hançer VS, Tokgöz H, Güvenç S, Çalışkan Ü, Büyükdoğan M. Three Novel Calreticulin Mutations in Two Turkish Patients. İki Türk Hastada Üç Yeni Kalretikulin Mutasyonu. Turk J Haematol. 2017.34(4):360-361. doi:10.4274/tjh.2017.0146 | 1 |
| 90 | 29411299 | Diep R, Metjian A. A rare CALR variant mutation and a review of CALR in essential thrombocythemia. J Thromb Thrombolysis. 2018.45(3):457-462. doi:10.1007/s11239-018-1619-0 | 1 |
| 91 | 29703677 | Luque Paz D, Boyer F, Beucher A, et al. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis. Blood Cells Mol Dis. 2018.71:75-76. doi:10.1016/j.bcmd.2018.04.002 | 1 |
| 92 | 31371984 | Nadiminti K, Silverman M, Bhagavathi S, Vikas P. t(15. 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma. Onco Targets Ther. 2019.12:5449-5455. Published 2019 Jul 11. doi:10.2147/OTT.S208290 | 1 |
| 93 | 32103564 | Ohtani H, Tanoi T, Azuma K, et al. Mass-forming extramedullary hematopoiesis of the spleen in a patient with CALR-mutated myeloproliferative neoplasm. Pathol Int. 2020.70(4):237-239. doi:10.1111/pin.12912 | 1 |
| 94 | 32591258 | Soliman EA, El-Ghlban S, El-Aziz SA, Abdelaleem A, Shamaa S, Abdel-Ghaffar H. JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2020.20(10):e645-e651. doi:10.1016/j.clml.2020.05.011 | 1 |
| 95 | 33344552 | Zhou FP, Wang CC, Du HP, Cao SB, Zhang J. Primary myelofibrosis with concurrent CALR and MPL mutations: A case report. World J Clin Cases. 2020.8(22):5618-5624. doi:10.12998/wjcc.v8.i22.5618 | 1 |